Medacta Group SA (MEDGF)
83.91
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Medacta Group Shareholders Equity (Quarterly): 364.82M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 364.82M |
| June 30, 2023 | 323.41M |
| June 30, 2023 | 323.41M |
| December 31, 2022 | 294.54M |
| June 30, 2022 | 263.47M |
| June 30, 2022 | 263.47M |
| December 31, 2021 | 256.33M |
| June 30, 2021 | 228.46M |
| Date | Value |
|---|---|
| June 30, 2021 | 228.46M |
| December 31, 2020 | 202.60M |
| June 30, 2020 | 152.20M |
| June 30, 2020 | 152.20M |
| December 31, 2019 | 138.04M |
| June 30, 2019 | 119.88M |
| June 30, 2019 | 119.88M |
| December 31, 2018 | 101.89M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
119.88M
Minimum
Jun 2019
364.82M
Maximum
Dec 2023
228.74M
Average
228.46M
Median
Jun 2021
Shareholders Equity (Quarterly) Benchmarks
| AC Immune SA | 191.25M |
| CRISPR Therapeutics AG | 1.883B |
| Addex Therapeutics Ltd | 1.364M |
| NLS Pharmaceutics Ltd | -4.287M |
| Molecular Partners AG | 210.05M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 769.22M |
| Total Liabilities (Quarterly) | 404.39M |
| Debt to Equity Ratio | 0.4885 |
| Current Ratio | 2.332 |
| Net Debt Paydown Yield | -3.55% |